Skip to main content

Survival outcomes following neoadjuvant therapy for resectable cholangiocarcinoma: a systematic review and reconstructed individual patient data meta-analysis

In brief

About 7 in 10 patients with resectable biliary cancer reached curative-intent surgery

Across six prospective trials, 71% of patients receiving preoperative treatment underwent curative-intent surgery; 51% were alive at three years. The findings suggest this approach is feasible for selected patients, but a substantial share did not reach curative surgery. Without randomized comparisons against current surgery-first care, its role in routine treatment remains uncertain.

Journal
Cancer treatment reviews (Q1)
Published
13 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Giovanni Trovato, Laura Chiofalo, Cinzia Bagalà, Francesca Belenghi, Kristian Shtembari, Daniele Lavacchi, et al.
PMID
43044180
DOI
10.1016/j.ctrv.2026.103243

Why clinicians should know about it

  • Picked for Surgery (top studies of the week, 22 November 2026): Neoadjuvant therapy and resection outcomes in cholangiocarcinoma

Abstract

BACKGROUND: The role of neoadjuvant systemic therapy in resectable biliary tract cancer (BTC) remains uncertain. We conducted a systematic review and meta-analysis to assess the feasibility, surgical outcomes, radiological activity, and survival associated with neoadjuvant treatment. METHODS: PubMed/MEDLINE, Embase, and CENTRAL were searched through April 30, 2026 for prospective phase II-III trials evaluating neoadjuvant systemic therapy followed by surgery in resectable BTC. Binary outcomes were pooled using random-effects models. Individual patient data were reconstructed from published Kaplan-Meier curves, and landmark survival estimates were synthesized using random-effects meta-analysis. RESULTS: Six prospective trials comprising seven active neoadjuvant treatment arms were included. Pooled neoadjuvant-to-surgery completion and curative-intent resection rates were 79.0% (95% CI, 63.0-89.0) and 71.0% (95% CI, 54.0-84.0), respectively. The pooled objective response rate was 21.2% (95% CI, 9.0-42.3), and the intention-to-treat R0 resection rate was 63.6% (95% CI, 44.7-79.0). Pooled overall survival was 84.0% (95% CI, 78.0-89.0), 63.0% (55.0-71.0), and 51.0% (44.0-59.0) at 12, 24, and 36 months, respectively. Corresponding recurrence-related survival estimates were 60.0% (51.0-69.0), 41.0% (33.0-50.0), and 37.0% (30.0-45.0). Findings were consistent across sensitivity analyses. CONCLUSION: Neoadjuvant systemic therapy is feasible in selected patients with resectable BTC, although a substantial proportion do not ultimately undergo curative surgery. Emerging prospective evidence supports further evaluation of perioperative strategies, particularly in high-risk disease, but randomized trials against contemporary surgery-first approaches are required before routine adoption.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.